Epivir

(Lamivudine)

ApprovedSmall molecule

Lamivudine is used to treat HIV infection and chronic hepatitis B by slowing down the reproduction of these viruses in the body, helping to reduce viral load and improve immune function.[2] Epivir is currently approved and in use across 44 indications[4].[1]

Epivir is one of 936 small molecule programs targeting Glioma. It is currently in Approved.

Indications

248

Total Trials

Active Trials

935

Competitors

FDA Applications

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[4][1]

Indication

GliomaActive, not recruiting

AIDSApproved

HIV InfectionActive, not recruiting

Cirrhosis of LiverApproved

Non-Hodgkins LymphomaApproved

Viral DiseaseActive, not recruiting

Hepatitis B Virus InfectionActive, not recruiting

OsteopeniaActive, not recruiting

Cognitive ImpairmentActive, not recruiting

HIV-Associated NephropathyApproved

GliomaPhase 1

Active, not recruiting

AIDSApproved

Approved

HIV InfectionApproved

Active, not recruiting

Cirrhosis of LiverApproved

Approved

Non-Hodgkins LymphomaApproved

Approved

Viral DiseaseApproved

Active, not recruiting

Hepatitis B Virus InfectionApproved

Active, not recruiting

OsteopeniaPreclinical

Active, not recruiting

Cognitive ImpairmentPhase 2

Active, not recruiting

HIV-Associated NephropathyApproved

Approved

Showing 10 of 43 indications

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Epivir

GGlaxo Dba Glaxosmithkline

Approved

1 2

Blenoxane

SSequus Pharmaceuticals

Preclinical

25 3

Zofran

Novartis

Preclinical

2 4

Norvir

AbbVie

Preclinical

1 5

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 6

Tafasitamab

Incyte

Preclinical

7 7

PEG-Intron

Merck & Co.

Preclinical

1 8

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

Systemic Therapy

1 10

Rhg-CSF

CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2026

Phase 1/2Active, not recruiting

Solid Tumors

NCT06494579

Q4 2026

Post-ApprovalNot yet recruiting

HBV Infection

NCT06503796

Q3 2027

Phase 2Recruiting

Small Cell Lung Cancer

NCT04696575

Q2 2029

Phase 2/3Active, not recruiting

Treatment

NCT02369406

Clinical

Trials by Indication[1]

Effectiveness22 trials

The Safety and Effectiveness of Lamivudine Plus Zidovudine, Used With and Without 1592U89, in HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 3·NCT00002389·210 enrolled

The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001075·55 enrolled

The Safety and Effectiveness of Zidovudine Plus Lamivudine, Used With and Without 1592U89, in HIV-1 Infected Children Who Have Taken Anti-HIV-1 Drugs

Completed· GSK logo

GSK·Phase 3·NCT00002391

Show 19 more trials

A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000922·1,710 enrolled

A Study to Compare the Effectiveness of Two Anti-HIV Drug Combinations

Completed· Merck & Co. logo

Merck & Co.·N/A·NCT00002430·220 enrolled

Safety and Effectiveness of Lamivudine When Given Once a Day Versus Twice a Day in Combination With Other Anti-HIV Drugs in HIV-Infected Adults Who Have Never Received Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00004852

Effectiveness and Safety of Epivir/Ziagen/Zerit (3TC/ABC/d4T) Versus Epivir/Ziagen/Sustiva (3TC/ABC/EFV) Versus Epivir/Ziagen/Agenerase/Norvir (3TC/ABC/APV/RTV) in HIV Patients Who Have Never Received Treatment

Unknown status· GSK logo

GSK·Phase 4·NCT00005017·300 enrolled

Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00005918·730 enrolled

Safety and Effectiveness of Giving Indinavir Plus Stavudine Plus Lamivudine to HIV-Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000901·24 enrolled

The Safety and Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Taken AZT

Completed· GSK logo

GSK·Phase 3·NCT00002436·325 enrolled

The Effectiveness of Nelfinavir and Efavirenz, Used Alone or Together, Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001087·300 enrolled

Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients

Completed·AAbbott·Phase 2·NCT00038220·40 enrolled

'COMBINE-2': Real-world Evidence for Effectiveness of Two Drug Regimen, Antiretroviral Therapy With Integrase Inhibitors Plus a Reverse Transcriptase Inhibitor

Completed· GSK logo

GSK··NCT04019873·774 enrolled

The Safety and Effectiveness of Adefovir Dipivoxil Plus Indinavir Combined With Zidovudine or Lamivudine or Stavudine in HIV-Infected Patients Who Have Not Taken Anti-HIV Drugs

Completed· Gilead logo

Gilead·Phase 2·NCT00002379·100 enrolled

The Effectiveness of Dual Therapy (Lopinavir/Ritonavir + LamivudinE) in Treatment-Experienced HIV Infected Patients in the Russian Federation

Completed· AbbVie logo

AbbVie··NCT02581202·216 enrolled

A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

Completed· GSK logo

GSK·Phase 2·NCT00002442

The Effectiveness of Indinavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients With No Symptoms of Infection

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002179·200 enrolled

Safety and Effectiveness of an Anti-HIV Drug Combination Taken Twice Daily

Unknown status· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002241·80 enrolled

The Safety and Effectiveness of Lamivudine Plus Stavudine or Zidovudine in HIV-Infected Patients Who Have Taken Zidovudine

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00002371·80 enrolled

A Study of the Safety and Effectiveness of Treating Advanced AIDS Patients Between Ages 4 and 22 With 7 Drugs, Some at Higher Than Usual Doses

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001108·6 enrolled

Safety and Effectiveness of Four Anti-HIV Drug Combinations in HIV-Infected Children and Teens

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001091·200 enrolled

A Study to Compare the Safety and Effectiveness of Indinavir Combined With Stavudine and Lamivudine

Suspended· Merck & Co. logo

Merck & Co.·Phase 2·NCT00002424·186 enrolled

Chronic Hepatitis21 trials

Safety and Antiviral Activity of Entecavir in Participants With Chronic Hepatitis B Following Monotherapy in Other Entecavir Trials

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01438424·1,053 enrolled

Lamivudine for Chronic Hepatitis B

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 2·NCT00001457·60 enrolled

Different Regimens of Pegylated Interferon and Lamivudine Combination Therapy in Chronic Hepatitis B Patients

Completed·—·Phase 2·NCT00226447·30 enrolled

Show 18 more trials

Lamivudine and Therapeutic Vaccine Evaluation in Senegalese Patients With Chronic Hepatitis B Infection (ANRS 12100 HEPADAK-2)

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00120796·8 enrolled

A Study of Pegylated Interferon Alfa-2A in Combination With Lamivudine or Entecavir Compared With Untreated Control Group in Children With Hepatitis B Envelope Antigen (HBeAg)-Positive Chronic Hepatitis B (CHB) in the Immune-Tolerant Phase

Completed· Roche logo

Roche·Phase 3·NCT02263079·62 enrolled

Efficacy of Clevudine Plus Lamivudine for Lamivudine-resistant Chronic Hepatitis B Patients

Terminated·IInje University·Phase 4·NCT00798460·30 enrolled

A Trial To Study The Effect Of Lamivudine In Adult Patients Who Suffer From Chronic Hepatitis B Alone

Completed· GSK logo

GSK·Phase 4·NCT00354653·100 enrolled

Comparison of Telbivudine Versus Lamivudine on the Early Dynamics and Kinetics of Viral Suppression in Chronic Hepatitis B

Withdrawn·UUniversity of Ulm·Phase 4·NCT00710216·40 enrolled

Tenofovir Versus Lamivudine for Patients of Chronic Hepatitis B With Severe Acute Exacerbation

Unknown status·KKaohsiung Veterans General Hospital.·Phase 3·NCT01848743·120 enrolled

Compare Continuing Lamivudine Plus Adefovir or Adefovir Versus Switching to Entecavir Plus Adefovir in Patients With LAM-resistant Chronic Hepatitis B

Unknown status·—·Phase 4·NCT02482272·90 enrolled

Lamivudine Plus Interferon Versus Lamivudine For The Treatment Of HBeAg Positive Chronic Hepatitis B Virus (HBV)

Completed· GSK logo

GSK·Phase 3·NCT00140725·160 enrolled

A Study of Pegylated Interferon Alfa-2a and Lamivudine in Patients With HBeAg-Negative Chronic Hepatitis B Virus (HBV)

Completed· Roche logo

Roche·Phase 3·NCT01095835·131 enrolled

Oxymatrine Plus Lamivudine Combination Therapy Versus Lamivudine Monotherapy for Chronic Hepatitis B Infected Subjects

Completed·SSoutheast University, China·Phase 4·NCT02202473·192 enrolled

Telbivudine Versus Lamivudine in Chinese Adults With Compensated Chronic Hepatitis B

Completed· Novartis logo

Novartis·Phase 3·NCT00131742

Switching Therapy From Lamivudine to Telbivudine Versus Continued Lamivudine in Adults With Chronic Hepatitis B

Completed· Novartis logo

Novartis·Phase 3·NCT00132652·240 enrolled

Safety and Efficacy of Adefovir Dipivoxil in Children and Adolescents With Chronic Hepatitis B

Completed· Gilead logo

Gilead·Phase 3·NCT00095121·173 enrolled

Lamivudine Extending Therapy in Chronic Hepatitis B Patients After 3-year of Oral Antiviral Agents

Unknown status·KKaohsiung Medical University Chung-Ho Memorial Hospital·Phase 4·NCT02337127·500 enrolled

A Study in Korea of Entecavir Versus Lamivudine in Adults With Chronic Hepatitis B Infection

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT00393484·122 enrolled

Telbivudine Versus Lamivudine in Adults With Decompensated Chronic Hepatitis B and Evidence of Cirrhosis

Completed· Novartis logo

Novartis·Phase 3·NCT00076336·232 enrolled

An Extension Study of Telbivudine, Lamivudine or Telbivudine Plus Lamivudine in Patients With Chronic Hepatitis B

Completed· Novartis logo

Novartis·Phase 2·NCT00124241

Entecavir Plus Adefovir Combination Therapy Versus Entecavir Monotherapy vs Therapy With Adefovir Plus Lamivudine for Chronic Hepatitis B Infected Subjects With Lamivudine-resistant Virus

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT00410202·629 enrolled

Treatment16 trials

Treatment With Nelfinavir or Efavirenz of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Unknown status·AAgouron Pharmaceuticals·Phase 4·NCT00005000·200 enrolled

Anti-HIV Treatment Interruptions in HIV Infected Adults in South Africa

Completed·TThe Wistar Institute·N/A·NCT00100646·30 enrolled

Evaluation of Two Anti-HIV Treatment Strategies in Resource-Limited South African Communities

Completed·CCIPRA SA·N/A·NCT00255840·812 enrolled

Show 13 more trials

Lamivudine Therapy in Patients With Prior Entecavir Treatment and Undetectable Viral Load

Completed·TThe University of Hong Kong·N/A·NCT01013272·50 enrolled

Comparison Between Lamivudine and Entecavir Treatment in Spontaneous Severe Acute Exacerbation

Terminated·TTaichung Veterans General Hospital·Phase 4·NCT01627223·17 enrolled

Treatment Success and Failure in HIV-Infected Subjects Receiving Indinavir in Combination With Nucleoside Analogs: A Rollover Study for ACTG 320

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000885·440 enrolled

Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158405·840 enrolled

Dolutegravir Plus Lamivudine Dual Therapy in Treatment Naïve HIV-1 Patients

Completed·AAdvancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections·Phase 2·NCT02582684·122 enrolled

Efficacy of Dolutegravir Plus Lamivudine in HIV-1-infected Treatment-naïve Adults Without a Baseline Genotyping Test

Completed·FFundacion IDEAA·Phase 4·NCT04549467·244 enrolled

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)

Completed· GSK logo

GSK·Phase 3·NCT02831673·719 enrolled

An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)

Completed· GSK logo

GSK·Phase 3·NCT02831764·722 enrolled

Tipranavir Dose-response Study Using a Prototype Self-emulsifying Drug Delivery System (SEDDS) Formulation in Treatment-naive HIV-1 Infected Patients Report on the Post-study Option, a Treatment of Triple Therapy With Delavirdine, ZDV and 3TC Without Tipranavir

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT02249130·18 enrolled

Real Life Study of Dolutegravir Plus Lamivudine in HIV-1-Infected Treatment-Naive Patients

Completed·UUniversity Hospital Virgen de las Nieves··NCT04002323·88 enrolled

Five-Drug Anti-HIV Treatment Followed by Treatment Interruption in Patients Who Have Recently Been Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000940·121 enrolled

Early Infant HIV Treatment in Botswana

Active, not recruiting·HHarvard School of Public Health (HSPH)·Phase 2/3·NCT02369406·67 enrolled

A Study of Saquinavir Soft Gelatin Capsules Plus Zidovudine Plus Lamivudine in the Treatment of HIV-1 Infected Patients Who Have Never Taken Anti-HIV Drugs

Completed· Roche logo

Roche·Phase 3·NCT00002367·40 enrolled

Drug15 trials

A Study of Two Anti-HIV Drug Combinations

Completed· GSK logo

GSK·N/A·NCT00002203

Comparison of GW433908/Ritonavir to Nelfinavir When Used With Abacavir and Lamivudine in Patients That Have Not Taken Antiretroviral Drugs

Unknown status· GSK logo

GSK·Phase 3·NCT00009061·624 enrolled

A Study of Three Different Anti-HIV Drug Combinations in HIV-Infected Patients

Completed· Merck & Co. logo

Merck & Co.·Phase 3·NCT00002410

Show 12 more trials

A Comparison of Two Anti-HIV Triple-Drug Combinations in HIV-Infected Patients

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002168·200 enrolled

A Study to Compare Two Anti-HIV Drug Combinations That Include Amprenavir in HIV-Infected Patients Who Have Failed Anti-HIV Drug Combinations That Did Not Include Amprenavir

Completed· GSK logo

GSK·Phase 2·NCT00002423·100 enrolled

A Study of Three Anti-HIV Drug Combinations in Patients Who Have Taken Amprenavir

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001095·94 enrolled

Preventing Sexual Transmission of HIV With Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00074581·3,526 enrolled

A Study of Three Drug Combination Therapies in HIV-Infected Patients Who Have Never Been Treated With Anti-HIV Drugs

Completed·WWeill Medical College of Cornell University·N/A·NCT00002407

Comparing FTC and Lamivudine in HIV-Infected Patients on a Stable Anti-HIV Drug Combination

Completed·TTriangle Pharmaceuticals·Phase 3·NCT00002416·390 enrolled

Dolutegravir Antiretroviral Strategy to Promote Improvement and Reduce Drug Exposure

Completed·BBabafemi Taiwo·Phase 3·NCT02263326·89 enrolled

Once-Daily Drug Regimen for HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001968·25 enrolled

Development of a Urine-Based Point-of-Care Test for Adherence to Antiretroviral Drugs

Completed·RRhonda Brand·Phase 1·NCT04302896·30 enrolled

A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs

Completed· Bristol-Myers Squibb logo

Bristol-Myers Squibb·N/A·NCT00002411

A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

Completed·PPharmacia and Upjohn·N/A·NCT00002400·45 enrolled

Simplified Drug Regimens for HIV Patients in ACTG 388 or Patients Who Responded to A First Potent Combination Regimen

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00014937·240 enrolled

HIV infection9 trials

Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00001644·42 enrolled

Combination Treatment With and Without Protease Inhibitors for Women Who Begin Therapy for HIV Infection During Pregnancy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00017719·440 enrolled

Safety and Efficacy of Fixed Dose Combination Dolutegravir/Abacavir/Lamivudine FDC Initiated During Acute HIV Infection

Completed·UUniversity of North Carolina, Chapel Hill·N/A·NCT02384395·40 enrolled

Show 6 more trials

Time to Protection and Adherence Requirements of Raltegravir With or Without Lamivudine in Protection From HIV Infection

Completed·GGuy's and St Thomas' NHS Foundation Trust·Phase 4·NCT03205566·38 enrolled

A Phase I Trial to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of 141W94 After Multiple Dosing in Patients With HIV Infection

Completed· GSK logo

GSK·Phase 1·NCT00002183·60 enrolled

Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000872·55 enrolled

A Phase I Study of Methotrexate for HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000834·30 enrolled

A Study to Evaluate Various Combinations of Anti-HIV Medications to Treat Early HIV Infection

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000919·900 enrolled

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00102960·377 enrolled

67 more indications

HIV8 trials

A Study of 141W94 Used Alone or in Combination With Zidovudine Plus 3TC in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001085·94 enrolled

Study of Anti-HIV Therapy Intensification

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00034086·22 enrolled

ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects

Completed·AAbbott·Phase 1/2·NCT00004578·100 enrolled

Show 5 more trials

Comparison of GW433908 and Nelfinavir in HIV Patients Who Have Not Had Antiretroviral Therapy

Unknown status· GSK logo

GSK·Phase 3·NCT00008554·210 enrolled

A Comparison of Lamivudine and Zidovudine, Used Alone and Together, in HIV-Infected Patients Who Have Not Used Zidovudine in the Past

Completed· GSK logo

GSK·Phase 3·NCT00002320·320 enrolled

A Study of Indinavir Sulfate Plus Zidovudine (AZT) Plus Lamivudine in HIV-Infected Patients Who Have Taken AZT for Six or More Months

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00000841·1,750 enrolled

A Study of Increased Lactic Acid and Abnormal Fat Distribution in HIV-Positive Patients

Completed· GSK logo

GSK·Phase 4·NCT00005764·100 enrolled

A HIV Study Of A Fixed-Dose Combination Tablet In Antiretroviral Experienced Patients

Completed· GSK logo

GSK·Phase 3·NCT00046176·240 enrolled

Children6 trials

The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000865·32 enrolled

A Comparison of Zidovudine Plus Lamivudine Versus ddI Used Alone or in Combination With Zidovudine in HIV-1 Infected Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001066·740 enrolled

Comparison of New Anti-HIV Drug Combinations in HIV-Infected Children Who Have Taken Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001083·240 enrolled

Show 3 more trials

A Study of Ritonavir (an Anti-HIV Drug) in HIV-Positive Infants and Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000952·60 enrolled

Safety and Pharmacokinetic Study of Fixed Dose Combination of Zidovudine, Lamivudine, and Nevirapine in HIV-Infected Children in Thailand

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00672412·42 enrolled

Drug Levels of Tablet and Liquid Forms of Lamivudine, Nevirapine, and Stavudine in HIV Infected Thai Children

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1/2·NCT00312091·44 enrolled

Hepatitis B5 trials

Nucleoside Analogue Prevent Vertical Transmission of Hepatitis B Virus

Completed·HHua Zhang·Phase 4·NCT01788371·700 enrolled

Entecavir Versus Lamivudine for Preventing the Risk of Hepatitis B Reactivation in NHL

Unknown status·FFudan University·Phase 2·NCT01914744·82 enrolled

Treatment of Hepatitis B Virus (HBV) Before Beginning Anti-HIV Drugs in Patients With Both HBV and HIV

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00051090

Show 2 more trials

A Randomized Controlled Trial of Lamivudine in Acute Hepatitis B

Completed·MMaulana Azad Medical College·Phase 4·NCT00380614

Study of Telbivudine and Lamivudine to Prevent Vertical Transmission of Hepatitis B

Completed·—·Phase 4·NCT01743079·700 enrolled

LAM5 trials

Entecavir Plus Adefovir in Lamivudine-Resistant Patients

Withdrawn· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 4·NCT00986778

Relative Bio-availability Study of Dolutegravir and Lamivudine Fixed Dose Combinations

Completed· GSK logo

GSK·Phase 1·NCT02738931·30 enrolled

REal-Life Cohort With DOlutegravir + LAmivudina

Completed·IInstituto de Investigación Sanitaria de la Fundación Jiménez Díaz··NCT04638686·185 enrolled

Show 2 more trials

Lamivudine and Adefovir Dipivoxil Fixed Dose Combination

Completed· GSK logo

GSK·Phase 1·NCT01353742·40 enrolled

Bioequivalence Study of Fixed Dose Versus Single Entities of Dolutegravir and Lamivudine

Completed· GSK logo

GSK·Phase 1·NCT03078556·154 enrolled

Pregnant Women4 trials

A Study to Evaluate the Safety and Tolerance of Stavudine (d4T) in Combination With Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000878·26 enrolled

A Study to Evaluate the Safety and Tolerance of Nelfinavir (NFV) Given With Zidovudine (ZDV) and Lamivudine (3TC) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000887·24 enrolled

A Study to Evaluate the Safety and Tolerance of Combination Anti-HIV Drug Therapy (Indinavir, Lamivudine, and Zidovudine) in HIV-Positive Pregnant Women and Their Infants

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000944·24 enrolled

Show 1 more trial

Safety and Effectiveness of Ritonavir Plus Lamivudine Plus Zidovudine in HIV-Infected Pregnant Women and Their Babies

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000888·14 enrolled

Itching3 trials

Continuing Lamivudine Versus Switching to Entecavir in Patients Who Achieved Undetectable HBV DNA

Completed·YYonsei University·Phase 4·NCT00625339·72 enrolled

Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM

Completed·JJudit Pich·Phase 3·NCT03311945·33 enrolled

Continuing Lamivudine vs Switching to Entecavir in Patients With Detectable HBV DNA

Completed·YYonsei University·Phase 4·NCT00625560·72 enrolled

Chemotherapy3 trials

A Randomized Study Comparing Lamivudine Versus Adefovir Dipivoxil for Prevention of zHBV Reactivation in HBsAg Seropositive Patients Undergoing Cytotoxic Chemotherapy

Unknown status·HHospital Authority, Hong Kong·N/A·NCT00489151·70 enrolled

A Study on the Effect of Chemotherapy Combined With Anti-HIV Drugs in HIV-Positive Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000899·10 enrolled

Comparison of Prophylactic Antiviral Efficacy in Patients Undergoing Chemotherapy: Entecavir Versus Lamivudine

Completed·SSeoul National University Hospital·Phase 3·NCT01580202·180 enrolled

Drug Therapy3 trials

A Study on the Management of Combination Anti-HIV Drug Therapy in HIV-Positive Children With Prior Treatment

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000902·217 enrolled

Treatment With Interleukin-2 (IL-2) Plus Combination Anti-HIV-Drug Therapy (HAART) for Patients Formerly in ACTG 328

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000923·110 enrolled

A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy

Completed·AAbbott·Phase 3·NCT00004583·660 enrolled

Tuberculosis3 trials

Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00091936·592 enrolled

Anti-HIV Drugs for Ugandan Patients With HIV and Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00078247·350 enrolled

Effectiveness of Anti-HIV Therapy (HAART) in HIV-Infected Patients With Tuberculosis

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00004736·44 enrolled

Efficacy and Safety3 trials

Trial to Evaluate Steady State Pharmacokinetic Parameters, Efficacy and Safety of Nevirapine in Antiretroviral Drug naïve Pediatric Patients

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 2·NCT00273975·123 enrolled

Comparison of Efficacy and Safety of Infant Peri-exposure Prophylaxis With Lopinavir/Ritonavir Versus Lamivudine to Prevent HIV-1 Transmission by Breastfeeding

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00640263·1,500 enrolled

Open-Label Study Comparing Efficacy and Safety of ATV/RTV+3TC With ATV/RTV+TDF/FTC in HIV-Infected, Treatment Naïve Subjects, Followed by Treatment With ATV/RTV+3TC

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 3·NCT01620944·3 enrolled

HIV-13 trials

A Comparison of Three Anti-HIV Drug Combinations Containing Saquinavir Soft Gelatin Capsules Used in HIV-1 Infected Patients

Completed· Roche logo

Roche·Phase 3·NCT00002378·825 enrolled

Pharmacokinetic and Safety Study of Raltegravir and Atazanavir in a Once Daily Dose Regimen in HIV-1 Infected Patients

Completed·RRadboud University Medical Center·Phase 2·NCT00943540·20 enrolled

New Tablet Containing Two FDA Approved Anti-HIV Drugs For Antiretroviral Therapy Experienced HIV-1 Infected Subjects

Completed· GSK logo

GSK·Phase 3·NCT00044577·166 enrolled

ART2 trials

Open-Label, 48-Week Extension Study of Elvucitabine in Combination With Background Antiretroviral Therapy (ART) for Participants Who Have Completed Study ACH443-014A

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00380159·4 enrolled

Study of Once Daily Elvucitabine Versus Lamivudine in Participants With a Documented M184V Mutation

Completed· AstraZeneca logo

AstraZeneca·Phase 1/2·NCT00312039·20 enrolled

Efficacy2 trials

Efficacy Optimizing Research of Lamivudine Therapy

Completed·NNanfang Hospital, Southern Medical University·Phase 4·NCT01088009·366 enrolled

Efficacy of Nevirapine Compared to ZDV + 3TC Administered in Labor and Again at Postdelivery in HIV Positive Women

Completed· Boehringer Ingelheim logo

Boehringer Ingelheim·Phase 3·NCT02181933·2,648 enrolled

Hepatitis C2 trials

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00100581·2 enrolled

An Open Label Study To Evaluate The Safety and Kinetics of Nelfinavir in Subjects With HIV and Hepatitis C

Completed· Pfizer logo

Pfizer·Phase 4·NCT00141284·12 enrolled

Tics2 trials

Pharmacokinetics of Atazanavir /Dolutegravir/Lamivudine Regimen as Maintenance Regimen

Terminated·RRadboud University Medical Center·Phase 2·NCT02566707·9 enrolled

Pharmacokinetics of Lamivudine at Two Different Doses

Completed·KKirby Institute·Phase 1/2·NCT00985647·24 enrolled

Pregnancy2 trials

Fortovase (Saquinavir) Given With Low-Dose Ritonavir, Zidovudine, and Lamivudine to HIV-Positive Pregnant Women During and After Pregnancy and to Their Newborns

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 1·NCT00000920·24 enrolled

The Effect of Anti-viral Drugs Used in Late Pregnancy on Long-term Development of Children

Unknown status·—··NCT02301650·400 enrolled

HIV-1 infection2 trials

Controlled Clinical Trial of Antiviral Cytotoxic T Lymphocyte (CTL) Infusion Following Combination Antiretroviral Drug Therapy for Asymptomatic HIV-1 Infection

Terminated·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00000875·16 enrolled

Safety, Efficacy and Dose-response Study of BMS-986001 in Subjects With HIV-1 Infection Who Are Treatment-naive

Terminated· Bristol-Myers Squibb logo

Bristol-Myers Squibb·Phase 2·NCT01489046·297 enrolled

Tenofovir2 trials

Darunavir/Ritonavir + Lamivudine Versus Darunavir/Ritonavir +Emtricitabine/Tenofovir in Naïve HIV-1 Infected Subjects

Completed·FFundación Huésped·Phase 4·NCT02770508·145 enrolled

Dosing of Tenofovir and Efavirenz in Antiretroviral Therapy

Completed·SShanghai Public Health Clinical Center·Phase 4·NCT02945163·184 enrolled

Immunodeficiency2 trials

A Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Antiviral Activity of Rilpivirine (TMC278) in Human Immunodeficiency Virus Infected Adolescents and Children Aged Greater Than or Equal to 6 Years

Completed· Johnson & Johnson logo

Johnson & Johnson·Phase 2·NCT00799864·54 enrolled

A Clinical Trial of GSK3640254 + Dolutegravir (DTG) in Human Immunodeficiency Virus-1 Infected Treatment-naive Adults

Terminated· GSK logo

GSK·Phase 2·NCT04900038·85 enrolled

Antiretroviral Treatment2 trials

Once-daily Highly Active Antiretroviral Treatment Regimen Administration in HIV-1 Infected Children in Burkina Faso (ANRS 12103 BURKINAME)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00122538·52 enrolled

Antiretroviral Treatment Guided by Proviral Genotype: Pilot Trial of Proof of Concept.

Unknown status·IInstituto de Investigación Hospital Universitario La Paz·Phase 2·NCT03539224·41 enrolled

Interaction2 trials

A Clinical Study of Islatravir and Its Interaction With Lamivudine (MK-8591-058)

Completed· Merck & Co. logo

Merck & Co.·Phase 1·NCT06811246·20 enrolled

A Phase IV, Open Label, 4-period Cross-over Study to Investigate a Drug Interaction Between Lamivudine and Sorbitol Oral Solutions in Healthy Volunteers

Completed· GSK logo

GSK·Phase 4·NCT02634073·16 enrolled

Immune System2 trials

Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00001119·288 enrolled

Effects of Two Anti-HIV Drug Combinations on the Immune Systems of HIV-Infected Patients Who Have Never Received Anti-HIV Drugs

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00004855·55 enrolled

Prevention1 trial

Prevention of Mother-to-child Transmission of HIV-1 Using a Responsive Intervention

Completed·AANRS, Emerging Infectious Diseases·Phase 3·NCT03870438·1,506 enrolled

Metastatic Colorectal Cancer1 trial

A Phase 2 Study of Lamivudine in Patients With p53 Mutant Metastatic Colorectal Cancer

Completed·MMassachusetts General Hospital·Phase 2·NCT03144804·36 enrolled

Terminated· Pfizer logo

Pfizer·Phase 3·NCT00650637·17 enrolled

Malaria1 trial

Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women

Completed·UUniversity of California, San Francisco·Phase 3·NCT00993031·389 enrolled

Hemophilia1 trial

Effect of Indinavir Plus Two Other Anti-HIV Drugs on Blood Clotting in HIV-Positive Males With Hemophilia

Completed· Merck & Co. logo

Merck & Co.·Phase 4·NCT00002386·55 enrolled

Resistance1 trial

Antiviral Activity of and Resistance to Lamivudine in Combination With Zidovudine, Stavudine, or Didanosine

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000838·256 enrolled

Infants1 trial

Pharmacokinetics of Antiretroviral Drugs in Lactating Women and Breastmilk Fed Infants Under 6 Months of Age in Botswana

Completed·—··NCT04862975·164 enrolled

Drug Resistance1 trial

Efficacy and Tolerability of an Antiretroviral Bi-Therapy in HIV Infected Patients With Multidrug Resistance

Terminated·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 2·NCT00120783·40 enrolled

Chronic Lymphocytic Leukemia1 trial

The Incidence of Hepatitis B Reactivations in Patients Affected by Chronic Lymphocytic Leukemia With Ibrutinib

Completed·GGruppo Italiano Malattie EMatologiche dell'Adulto··NCT03528941·109 enrolled

Lymphoma1 trial

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

Withdrawn·UUniversity of Michigan Rogel Cancer Center·Phase 1/2·NCT01528865

Adult T-Cell Leukemia/lymphoma1 trial

Combination Chemotherapy Followed By Antiviral Therapy and Interferon Alfa in Treating Patients With HTLV-1-Related Adult T-Cell Leukemia/Lymphoma

Completed·AAIDS Malignancy Consortium·Phase 2·NCT00041327·19 enrolled

Impaired Renal Function1 trial

Evaluation of Renal Function, Efficacy, and Safety When Switching From Tenofovir/Emtricitabine Plus a Protease Inhibitor/Ritonavir, to a Combination of Raltegravir (MK-0518) Plus Nevirapine Plus Lamivudine in HIV-1 Participants With Suppressed Viremia and Impaired Renal Function (MK-0518-284)

Terminated· Merck & Co. logo

Merck & Co.·Phase 2·NCT02116660·11 enrolled

CLE1 trial

Nucleosides And Darunavir/Dolutegravir In Africa

Unknown status·MMakerere University·Phase 3·NCT03988452·465 enrolled

Cirrhosis1 trial

Special Drug Use Investigation for ZEFIX (Lamivudine) Tablet (HBV Cirrhosis)

Completed· GSK logo

GSK··NCT01376154·342 enrolled

Newborns1 trial

Antiretroviral Regime for Viral Eradication in Newborns

Completed·NNational Center for Women and Children's Health, China CDC·Phase 4·NCT02712801·600 enrolled

Advanced1 trial

Immunologic and Virologic Consequences of Long-Term Highly Active Antiretroviral Therapy (HAART) in Subjects With Moderately Advanced HIV-1 Disease: A Follow-Up Study to ACTG 315

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000891·34 enrolled

Double-blind1 trial

A Double-Blind, Randomized, Dose Response Study of Three Doses of Delavirdine Mesylate (U-90152S) in Combination With Zidovudine (ZDV) Versus ZDV Alone in HIV-1 Infected Individuals With CD4 Counts of 200-500mm3

Completed·PPharmacia and Upjohn·Phase 3·NCT00002124·1,250 enrolled

Small Cell Lung Cancer1 trial

Lamivudine in Combination With Chemoimmunotherapy for the Treatment of Extensive Stage Small Cell Lung Cancer

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT04696575·28 enrolled

Child1 trial

Preventing Childhood HIV: Rescue Intervention. ANRS 12388 PREVENIR-PEV

Unknown status·AANRS, Emerging Infectious Diseases·Phase 2·NCT03869944·97 enrolled

Aicardi-Goutières syndrome1 trial

Inhibition of Reverse Transcription in Aicardi-Goutières Syndrome

Completed·UUniversity of Edinburgh·Phase 2·NCT04731103·13 enrolled

Cognitive impairment1 trial

A Single-center, Self-controlled, Prospective Case Series Pilot Study to Assess the Effect of Lamivudine (3TC) on Neurocognitive Impairment Biomarkers and Type-I IFN (Interferon)-Stimulated Genes in the Plasma of Patients With Mild Cognitive Impairment (MCI)

Active, not recruiting·FFundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia·Phase 2·NCT06519357·23 enrolled

Solid Organ Transplant1 trial

Clinical Trial to Evaluate the Efficacy, Pharmacokinetics (PK) Interactions and Safety of Dolutegravir Plus 2 Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in HIV-1-Infected Solid Organ Transplant Patients

Completed·FFundacion Clinic per a la Recerca Biomédica·Phase 4·NCT03360682·19 enrolled

Retinal Detachment1 trial

Lamivudine and Plasma Markers of Inflammation in Retinal Detachment

Terminated·UUniversity of Wisconsin, Madison·Phase 1·NCT06056596·2 enrolled

HBV Infection1 trial

Antiviral Therapy in Infants With HBV Infection

Not yet recruiting·—·Phase 4·NCT06503796·60 enrolled

Monotherapy1 trial

Virologic Responses To New Nucleoside Regimens After Prolonged ZDV or ddI Monotherapy

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00000831·280 enrolled

Osteopenia1 trial

Simplification From Tenofovir Plus Lamivudine or Emtricitabine Plus Ritonavir-Boosted-Protease Inhibitor to Ritonavir-Boosted-Atazanavir Plus Lamivudine in Virologically-Suppressed-HIVInfected Adults With Osteopenia

Completed·JJudit Pich·N/A·NCT02652793·31 enrolled

Safety and Efficacy1 trial

A Phase II, Stratified, Randomized, Double-Blind, Multi-Center Study of the Safety and Efficacy of Adefovir Dipivoxil (ADF) at Two Dose Levels in Triple Combination Therapies With Protease Inhibitors (PI) and Nucleoside Reverse Transcriptase Inhibitors (RTI) for the Treatment of HIV-Infected Patient

Completed· Gilead logo

Gilead·Phase 2·NCT00002184·120 enrolled

Disease Progression1 trial

A Study of Disease Progression and Anti-HIV Treatments

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00001068·210 enrolled

Chronic HBV Infection1 trial

Influence of Antiviral Treatment to the Long-Term Prognosis of Patients With Chronic HBV Infection

Unknown status·SSun Yat-sen University·Phase 4·NCT00810524·600 enrolled

Clinical Trial1 trial

Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial

Completed·—·Phase 4·NCT02431975·73 enrolled

Kidney Disease1 trial

A Study of Saquinavir Soft Gel Capsules (SGC) Used in Combination With Two Other Anti-HIV Drugs in Patients With HIV-Associated Kidney Disease

Completed· Roche logo

Roche·Phase 3·NCT00002397·24 enrolled

Chronic Hepatitis B Virus Infection1 trial

Safety and Antiviral Activity Study of ACH-126,443 (Beta-L-Fd4C) in Treatment-naive Adults With Chronic Hepatitis B Virus Infection

Completed· AstraZeneca logo

AstraZeneca·Phase 2·NCT00034359·79 enrolled

Intensive Care1 trial

Potent Antiviral Therapy for Critically Ill HIV Infected Patients Admitted to Intensive Care

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00028327·250 enrolled

Solid Tumors1 trial

Lamivudine for Solid Tumors

Active, not recruiting·TThomas Marron·Phase 1/2·NCT06494579·12 enrolled

Combination Therapy1 trial

Four-Drug Combination Therapy With Zidovudine, Lamivudine, 1592U89 (Abacavir), and 141W94 (Amprenavir) in HIV-Infected Patients

Completed·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006617·25 enrolled

Immune Response1 trial

Evaluation of Specific Infection-Fighting Cells For Prediction of Immune Response to Anti-HIV and Immune-Boosting Medication

Withdrawn·NNational Institute of Allergy and Infectious Diseases (NIAID)·N/A·NCT00006578

Kidney Transplant1 trial

Renal Function Improvement in HBsAg Positive Kidney Transplantation Patients Under Telbivudine Treatment.

Terminated·NNational Taiwan University Hospital·Phase 4·NCT02894554·19 enrolled

Randomized1 trial

A Randomized, Parallel Arm, Comparative, Open Label, Multicenter Study of the Activity and Safety of Two Formulations of Saquinavir in Combination With Other Antiretroviral Drugs

Completed· Roche logo

Roche·Phase 2·NCT00002162·140 enrolled

Drug Interactions1 trial

Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen

Terminated·JJudit Pich·Phase 3·NCT03333083·17 enrolled

Phase II1 trial

A Phase II Open-Label Exploratory Study of Saquinavir + Zidovudine + Lamivudine in HIV Infected Patients

Completed· Roche logo

Roche·Phase 2·NCT00002190·30 enrolled

Lipodystrophy1 trial

A Study to Determine How and Why HIV-Infected Subjects on Anti-viral Treatment Develop Lipodystrophy

Completed·NNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)·Phase 4·NCT00006190

Systemic Inflammation1 trial

A Study of Exercise and Pharmacologic Intervention on Systemic Inflammation

Recruiting·IIcahn School of Medicine at Mount Sinai·Phase 1·NCT07058974·22 enrolled

Unspecified5 trials

Feasibility Study of a Once Daily Antiretroviral Regimen in Vietnam (ANRS 1210 VIETAR)

Completed·FFrench National Agency for Research on AIDS and Viral Hepatitis·Phase 3·NCT00158470·100 enrolled

Optimization of Antiretroviral Therapy

Completed·SShanghai Public Health Clinical Center·Phase 4·NCT02935075·184 enrolled

ANRS 12372 MODERATO Study

Unknown status·AANRS, Emerging Infectious Diseases·Phase 3·NCT04022967·480 enrolled

Show 2 more trials

An Exploratory Study of RGT Strategy on Optimal NUC-experienced Patients

Unknown status·RRuijin Hospital·Phase 4·NCT02560649·324 enrolled

Test Albuvirtide in Experienced Patients

Completed·FFrontier Biotechnologies Inc.·Phase 3·NCT02369965·418 enrolled

Regulatory

FDA Approval Timeline[5]

Nov 17, 1995

EPIVIR

NDA NDA020596

Nov 17, 1995

EPIVIR

NDA NDA020564

Dec 8, 1998

EPIVIR-HBV

NDA NDA021004

Dec 8, 1998

EPIVIR-HBV

NDA NDA021003

Sources

References

[1]
ClinicalTrials.gov — 248 trial records for Lamivudine. U.S. National Library of Medicine, National Institutes of Health.
[2]
MedlinePlus Drug Information — Epivir drug information. U.S. National Library of Medicine, National Institutes of Health.
[3]
ChEMBL — Lamivudine compound record. European Bioinformatics Institute (EMBL-EBI).
[4]
Open Targets Platform — Drug–disease associations for Lamivudine. EMBL-EBI & Wellcome Sanger Institute.
[5]
OpenFDA — FDA approval records (NDA NDA021004). U.S. Food & Drug Administration.
[6]
SEC EDGAR — Glaxo Dba Glaxosmithkline company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Mechanism of Action: Human Immunodeficiency Virus Type 1 Reverse Transcriptase Inhibitor; DNA Polymerase/reverse Transcriptase Inhibitor[3]
Modality: Small molecule[3]
Highest Phase: Approved[1]
Company: GGlaxo Dba Glaxosmithkline

Epivir

Status by Indication[4][1]

Competitive Landscape

Expected Milestones

Q3 2026

Q4 2026

Q3 2027

Q2 2029

Trials by Indication[1]

Effectiveness22 trials

Chronic Hepatitis21 trials

Treatment16 trials

Drug15 trials

HIV infection9 trials

HIV8 trials

Children6 trials

Hepatitis B5 trials

LAM5 trials

Pregnant Women4 trials

Itching3 trials

Chemotherapy3 trials

Drug Therapy3 trials

Tuberculosis3 trials

Efficacy and Safety3 trials

HIV-13 trials

ART2 trials

Efficacy2 trials

Hepatitis C2 trials

Tics2 trials

Pregnancy2 trials

HIV-1 infection2 trials

Tenofovir2 trials

Immunodeficiency2 trials

Antiretroviral Treatment2 trials

Interaction2 trials

Immune System2 trials

Prevention1 trial

Metastatic Colorectal Cancer1 trial

Vaccination1 trial

Liver1 trial

Diarrhea1 trial

Malaria1 trial

Hemophilia1 trial

Resistance1 trial

Infants1 trial

Drug Resistance1 trial

Chronic Lymphocytic Leukemia1 trial

Lymphoma1 trial

Adult T-Cell Leukemia/lymphoma1 trial

Impaired Renal Function1 trial

CLE1 trial

Cirrhosis1 trial

Newborns1 trial

Advanced1 trial

Double-blind1 trial

Small Cell Lung Cancer1 trial

Child1 trial

Aicardi-Goutières syndrome1 trial

Cognitive impairment1 trial

Solid Organ Transplant1 trial

Retinal Detachment1 trial

HBV Infection1 trial

Monotherapy1 trial

Osteopenia1 trial

Safety and Efficacy1 trial

Disease Progression1 trial

Chronic HBV Infection1 trial

Clinical Trial1 trial

Kidney Disease1 trial

Chronic Hepatitis B Virus Infection1 trial

Intensive Care1 trial

Solid Tumors1 trial

Combination Therapy1 trial

Immune Response1 trial

Kidney Transplant1 trial

Randomized1 trial

Drug Interactions1 trial

Phase II1 trial

Lipodystrophy1 trial

Systemic Inflammation1 trial